With chronic models support the general opinion that rapamycin protects by inducing long-term cellular changes. Rapamycin also protected against seizures when administered after the initial induction of status epilepticus in the pilocarpine rat model, raising the possibility that rapamycin also may act acutely to inhibit seizure activity. However, rapamycin failed to protect when the same post-treatment model of pilocarpine-induced status epilepticus was applied to mice and it did not protect against seizures during the first 48 hours after a hypoxic insult in P10 rats, challenging the idea that rapamycin has acute antiseizure effects. Similarly, attempts to study the short-term effects of rapamycin in vitro also have not provided strong support for acute effects of rapamycin. Short-term exposure of neurons in vitro to rapamycin did not alter neuronal firing under baseline conditions, and it had limited benefits under conditions of provoked neuronal firing. One way to determine if rapamycin acutely suppresses seizure activity is to compare it to known anticonvulsants. Rapamycin has not been systematically tested in a battery of acute seizure tests like those used routinely to screen candidate therapeutics in preclinical trials. Using similar tests, we found that rapamycin has a limited acute anticonvulsant effect. Furthermore, rapamycin exposure for #6 h has a profile that is comparable to drugs that suppress voltage-gated sodium channel activity. Even when tested for order PF-CBP1 (hydrochloride) longer times, rapamycin still has an acute seizure test profile that does not match the profiles of either the ketogenic diet or another dietary antiseizure intervention, intermittent fasting. Thus, the anticonvulsant mechanisms of rapamycin may be distinct from other metabolism-based therapies. Because of the adverse effects of rapamycin and related drugs in patients, finding an explanation for how mTOR inhibition protects against seizures could help facilitate the design of more specific agents and minimize side effects. The Anticonvulsant Screening Project funded by the National Institute of Neurological Disease and Stroke screens dozens of potential compounds annually for potential therapeutic use. By adjusting dosing parameters, we adapted these tests to permit K858 direct comparisons with me
